Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesDental/Oral & MaxillofacialBlue Cross Blue Shield WI LDCA/LDAA Coverage | Ope…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - WisconsinPolicy 04-302

    Local Delivery of Chemotherapeutic Agents/Antimicrobial Agents (LDCA/LDAA)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Wisconsin Policy 04-302 alerts

    Get alerted when Policy 04-302 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the use of locally delivered chemotherapeutic or antimicrobial agents (LDCA/LDAA) as adjunctive therapy in periodontal disease management for Blue Cross Blue Shield - Wisconsin members, addressing indications, contraindications, required documentation, and coding guidance.

    Policy Summary
    PayerBlue Cross Blue Shield - Wisconsin
    PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents (LDCA/LDAA)
    Policy CodePolicy 04-302
    Change TypeMinor — no material clinical or coverage changes
    Effective Date
    Last ReviewOct 28, 2024
    Next Review DateJan 1, 2025
    Key ActionObtain a current (within 12 months) dated 6-point periodontal charting and ensure target sites have a probing depth ≥ 5 mm after definitive therapy before performing LDCA/LDAA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >=5min probing depth (mm)
    6w-6m

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    healing interval
    12 mocharting recency
    D4381, D4341...referenced CDT codes

    Coverage Criteria for Local Delivery Agents

    Coverage criteria for LDCA/LDAA

    Covered when ALL of the following are met

    Prerequisite therapy: Definitive non-surgical (scaling and root planing) and/or surgical periodontal treatment has been completed and adequate time for healing has been allowed.6 weeks to 6 months post-therapy

    Per policy: allow 6 weeks to 6 months after scaling/root planing or periodontal surgery before local delivery.

    Site characteristics: Target tooth/site demonstrates a periodontal pocket measuring 5 mm or greater with persistent signs of inflammation (spontaneous bleeding, bleeding on probing, or suppuration) and a history of increasing pocket depth with associated clinical attachment loss.>= 5 mm

    Defines refractory disease site and minimum probing depth requirement.

    Extent limitation: Indication limited to isolated, localized refractory or recurrent/residual sites (including during periodontal maintenance); not appropriate for generalized periodontitis where comprehensive or surgical therapy is indicated.localized

    Policy excludes generalized periodontitis as an indication and notes surgical therapies may be necessary.

    Documentation: A current (within 12 months), dated, post-periodontal maintenance and/or post-periodontal surgery 6-point periodontal charting is required; medically compromised patients require physician documentation and will be reviewed case-by-case.charting within 12 months

    Documentation and case-by-case review requirements per policy.

    Tooth selection: Only natural teeth with favorable periodontal outcomes will be considered for benefit.

    Policy limits benefit to natural teeth with favorable outcomes.

    The use of locally delivered chemotherapeutic or antimicrobial agents (LDCA/LDAA) for the purpose of regeneration of alveolar bone is considered experimental and investigational and is excluded from coverage.

    LDCA/LDAA modalities are not appropriate for periodontal probing depths of less than 5 mm. When a generalized pattern of periodontitis is diagnosed, more comprehensive intervention—such as periodontal surgical therapies—may be necessary and isolated local delivery is not indicated.

    These agents are intended for isolated, refractory or localized recurrent/residual sites encountered during periodontal maintenance after definitive therapy, not for generalized disease. Providers should confirm that root planing or other definitive non‑surgical therapy has been completed and allow an adequate healing interval before local delivery is performed.

    Relevant Codes and Billing Thresholds

    Relevant CDT CodesCDT
    D4381Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth
    D4341Periodontal scaling and root planing, four or more teeth per quadrant
    D4342Periodontal scaling and root planing, one to three teeth per quadrant
    D4346Scaling in the presence of generalized moderate or severe gingival inflammation full mouth, after oral exam
    D4910Periodontal maintenance
    D4999Unspecified periodontal procedure, by report
    D6081Scaling and debridement in the presence of inflammation or mucositis of a single implant, including cleaning of the implant surfaces, without flap entry and closure.
    Probing depth threshold — minimum eligible pocket depth
    Minimum eligible pocket depth>= 5 millimeters (mm)
    Timing after definitive therapyAllow 6 weeks to 6 months post scaling and root planing or periodontal surgery before local delivery
    ApplicabilityTarget sites are active/refractory pockets demonstrating persistent inflammation or bleeding

    Provider Requirements, Sequencing, and Denial Triggers

    Prior Authorization

    Prior authorization / coding note — D4381

    CDT code D4381 (Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth) is listed as an applicable procedure code; verify member contract benefits and prior authorization requirements for D4381 with the payer before billing or performing the service.

    • Inclusion of a code in the policy does not guarantee coverage or reimbursement; check member contract benefits.
    • Prior authorization requirements are not explicitly stated in this document and must be confirmed with the plan.
    Step Therapy

    Therapy sequencing — adjunctive use after definitive periodontal therapy

    LDCA/LDAA are considered adjunctive therapies and should only be used after definitive non-surgical (scaling and root planing) and/or surgical periodontal treatment has been completed and an adequate healing interval allowed.

    • Allow a healing period of six weeks to six months after scaling and root planing or periodontal surgery before performing local delivery.

    Background and Rationale

    Scaling and root planing is the standard non‑surgical therapy for chronic periodontitis and is highly effective in the majority of diseased sites; most will respond and will not require adjunctive local antimicrobial delivery.

    Local delivery of antimicrobial agents is considered an adjunctive therapy after definitive non‑surgical (scaling and root planing) and/or surgical periodontal treatment. An adequate healing period of 6 weeks to 6 months post‑therapy should be allowed before performing local delivery, and treated teeth must demonstrate an active/refractory site (typically a periodontal pocket of >= 5 mm with persistent signs of inflammation).

    Key Definitions

    Refractory disease site — definition including pocketing >= 5 mm with persistent signs of inflammation/bleeding
    DefinitionAn area with periodontal pocketing equal to or greater than 5 millimeters (mm) with persistent signs of inflammation, spontaneous bleeding or bleeding on probing, suppuration and/or increasing loss of clinical attachment.
    Clinical contextEvaluation for LDCA/LDAA is made after completion of definitive non-surgical and/or surgical periodontal treatment; may also be indicated for isolated refractory sites at periodontal maintenance visits.
    Site characteristicsUsually described as an active/refractory site with history of increasing pocket depth and associated attachment loss.
    Policy Summary
    PayerBlue Cross Blue Shield - Wisconsin
    PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents (LDCA/LDAA)
    Policy CodePolicy 04-302
    Change TypeMinor — no material clinical or coverage changes
    Effective Date
    Last ReviewOct 28, 2024
    Next Review DateJan 1, 2025
    Key ActionObtain a current (within 12 months) dated 6-point periodontal charting and ensure target sites have a probing depth ≥ 5 mm after definitive therapy before performing LDCA/LDAA.
    SourceLink
    On This Page
    Coverage Criteria for Local Delivery AgentsRelevant Codes and Billing ThresholdsProvider Requirements, Sequencing, and Denial TriggersBackground and RationaleKey Definitions
  1. Appropriate for isolated/refractory sites or localized recurrent/residual sites encountered during periodontal maintenance, not for generalized periodontitis.
    2. Documentation Required

    Required documentation — dated 6‑point periodontal charting within 12 months

    A current, dated 6‑point periodontal charting performed within the prior 12 months is required and must be included in the patient record; medically compromised patients require physician documentation for case‑by‑case review.

    • Charting must be post-periodontal maintenance and/or post-periodontal surgery and dated within 12 months.
    • Only natural teeth with favorable periodontal outcomes will be considered for benefit.
    Denial Risk

    Denial triggers — non-covered concurrent services and clinical exclusions

    Services performed in conjunction with or in preparation for a non-covered or denied service will also be not covered or denied; LDCA/LDAA are not appropriate for sites with probing depths less than 5 mm and are not indicated for generalized periodontitis where more comprehensive therapy is required.

    • LDCA/LDAA modalities are not appropriate for periodontal probing depths < 5 mm.
    • When generalized periodontitis is diagnosed, surgical therapies or more comprehensive interventions should be considered; isolated local delivery may be denied in that context.